# Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

> **NCT03708536** · PHASE3 · WITHDRAWN · sponsor: **Fujian Cancer Hospital**

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** S-1
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03708536
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11
- **Primary completion:** 2021-11
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There are no fund to support
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708536, "Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03708536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*